Intravascular stent

By using a combination of perforated outer collagen layer and inner collagen layer in the vascular stent, the production of nitric oxide was promoted, and the stenosis and occlusion problems caused by SMC endometrial hyperplasia after surgery were solved, and the grafts were improved. Success rate and vascular healing effect.

CN118900665AInactive Publication Date: 2024-11-05NEWTEC VASCULAR PRODUCTS LIMITED

Patent Information

Application Number
CN202380028374.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-08
Filing Date
2023-03-08
Publication Date
2024-11-05
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure CN118900665A_ABST
    Figure CN118900665A_ABST
Patent Text Reader

Abstract

An intravascular stent for placement around the exterior of a circulating anastomotic stoma is disclosed. The intravascular stent includes a laminate having a biodegradable inner collagen layer and a perforated outer collagen layer disposed about the biodegradable inner collagen layer. A method of using the intravascular stent in an arteriovenous bypass graft procedure and a kit including the intravascular stent and instructions for using the intravascular stent in an arteriovenous bypass graft procedure are also disclosed.
Need to check novelty before this filing date? Find Prior Art

Description

Background Art

[0001] Neointimal hyperplasia represents the increase of the quantity of smooth muscle cells (SMC) between the endothelium and the internal elastic lamina of blood vessel.When intimal hyperplasia occurs, the intimal layer or the vascular wall may be caused to thicken again, causing the vessel to be fast and gradually narrowed, or even occluded (usually relevant to thrombosis).When the intima of blood vessel is damaged, deformed or disturbed during operation, the proliferation of arterial SMC usually occurs.Surgical anastomosis (particularly relevant to bypass graft (wherein vein or synthetic substitute is anastomosed to artery)) may cause SMC proliferation usually, and therefore cause stenosis.

[0002] In the first one to six months after surgery, a considerable number of arterial bypass grafts fail, i.e. become occluded, but occlusion may still occur in the next two years. In these cases, SMC intimal hyperplasia is often the cause of stenosis of the vessel lumen, which may eventually cause complete occlusion. SMC intimal hyperplasia most often occurs around the more distal (usually the venous end) anastomosis and in the "native" vessel wall opposite the anastomosis. SMC intimal hyperplasia may also occur at the proximal arterial anastomosis and along parts of the graft itself.

[0003] The graft is typically anastomosed to the native vessel in one of three ways: “end-to-end,” “end-to-side,” or “side-to-side.” Of these techniques, end-to-side and side-to-side are more common than end-to-end.

[0004] WO 2007 / 010295 A1 discloses an external vascular stent having a substantially non-porous outer layer and a biodegradable inner layer. The outer layer is relatively rigid and provides a structural framework, while the inner layer degrades relatively quickly.

[0005] When the stent of WO 2007 / 010295 A1 is implanted around the anastomosis, the stent attracts exudate, and new microvessels begin to grow, and this is mainly due to its internal collagen sponge structure. These microvessels (which are endothelial cells with single cell wall thickness at first) eventually tend to produce a large amount of nitric oxide, and known nitric oxide can directly suppress the accumulation of SMC on the inside of the anastomosis. Therefore, increasing the speed of microvessel formation will reduce the accumulation of SMC, thereby limiting SMC neointimal hyperplasia, and improving the success rate of vascular bypass grafts thus. Summary of the invention

[0006] According to a first aspect of the present invention, a vascular stent is provided for placement around the outside of a circulatory anastomosis; the vascular stent comprises a laminate having a biodegradable inner collagen (sponge) layer and a perforated outer (dense) collagen (sheet) layer arranged around the biodegradable inner collagen layer.

[0007] When using the prior art stent of WO 2007 / 010295 A1, the outer collagen layer is so dense that it takes several months to be engulfed by macrophages circulating in the bloodstream; while the inner collagen layer is relatively biodegradable and will ideally be engulfed in about one to four weeks. However, during the first few days (before the inner collagen layer has been engulfed), the surface area of ​​the inner collagen layer presented to the early microvessels (and thus the macrophages) is relatively small (i.e., only the ends of the inner collagen layer). Therefore, this limits the production of nitric oxide during the first few days after surgical implantation of the stent.

[0008] The use of a perforated outer collagen layer in the present invention allows microvessels to grow inward from the outside of the device and increases the size of the surface area of ​​the unperforated inner collagen layer that is presented to the microvessels from the outset and can therefore be immediately engulfed. This in turn promotes the growth of nitric oxide-producing cells, thereby increasing the overall production of nitric oxide and improving the distribution of nitric oxide along the length of the stent. Therefore, compared with the stent of WO 2007 / 010295 A1, the perforated outer layer reduces the accumulation of SMCs and improves the success rate of arterial bypass grafts.

[0009] A circulatory anastomosis is an anastomosis between two blood vessels (e.g., between two veins, between two arteries, or between a vein and an artery, or between a vessel and a bypass graft, which itself may be a natural or synthetic material). Any reference to an anastomosis herein should be understood to refer to a circulatory anastomosis.

[0010] Lamination means that the vascular stent is formed of adhesive layers, ie, an inner collagen layer and an outer collagen layer.

[0011] A vascular stent may be referred to herein simply as a stent, or it may be referred to as an external stent or external vascular stent, where the term "external" refers to the fact that the stent is intended to be placed around the outside of a blood vessel (rather than within the vessel).

[0012] The inner and / or outer collagen layers may be formed from collagen materials derived from bovine, or porcine, or other natural or artificial sources, and are preferably predominantly collagen type I. The outer collagen layer may be, for example, a dermal, pericardial or peritoneal collagen membrane.

[0013] The outer collagen layer comprises a plurality of pores (ie through-holes or perforations). The pores may be substantially elliptical (eg circular), or they may have other regular or irregular shapes.

[0014] Preferably, each hole of the plurality of holes has a diameter (ie the distance between opposite sides of the hole) of 0.1 mm to 5.0 mm, even more preferably 0.1 mm to 0.5 mm.

[0015] Using holes of this size allows microvasculature and therefore macrophages to reach the inner collagen layer, while also ensuring that the outer collagen layer is not structurally weakened (the outer collagen layer acts as a scaffolding element around the anastomosis) and preventing leakage of the inner collagen layer through the holes (at the time of manufacture).

[0016] Preferably, the distance (spacing) between adjacent (ie nearest neighbor) holes is 1 mm to 10 mm. The holes may be positioned regularly (e.g. in a grid) or irregularly (e.g. with different spacings between different pairs of adjacent holes). The density of the holes may be 10 mm per square inch. 2 1 hole per mm 2 0.01 hole (i.e. every 100mm 2 1 hole).

[0017] Using this spacing distance (or density) ensures that microvascular growth (and therefore nitric oxide production) is evenly distributed along the length of the stent, while also maintaining the structural integrity of the outer collagen layer.

[0018] The vascular stent is preferably elongated (ie, long relative to its width). It can be cut to provide longer and shorter lengths, which in turn can be appropriately placed around different forms of vascular anastomoses.

[0019] The profile of the stent in a plane perpendicular to the longitudinal axis of the stent may be elliptical (eg, oval or circular) or arcuate (ie, the stent may have an elliptical or arcuate cross-section through the axial extent of the stent).

[0020] Having an oval (eg circular) profile (ie being formed as a tube) means that the stent must be implanted during bypass surgery by passing it through one of the blood vessels before connecting the two vessels (eg during an end-to-end connection).

[0021] Having an arcuate profile means that the stent can instead be implanted after the vessel has been joined, for example by opening the vessel (using an incision along the length of the stent) and positioning it around the vessel, or by positioning the stent over the vessel like a saddle.

[0022] The angle subtended by the arcuate portion may be less than 270°.

[0023] Preferably, the outer collagen layer has a thickness of 0.1 mm to 1.0 mm. This thickness allows the outer collagen layer to have sufficient strength to support the inner collagen layer and the anastomosis while still being easy to handle and implant. This thickness also helps ensure that the outer layer has a suitable degradation profile.

[0024] Preferably, the outer collagen layer has a degradation profile such that the outer collagen layer is retained for at least three months after implantation in a human or animal body, and preferably for three to six months. That is, the properties of the outer collagen layer (e.g., thickness and material) are selected such that the structural integrity of the outer collagen layer is maintained during at least the first three months after implantation of the scaffold in a human or animal body.

[0025] Preferably, the inner collagen layer has a degradation profile such that the inner collagen layer is retained for a minimum of seven days and / or a maximum of 28 days after implantation in a human or animal body. That is, the properties of the inner collagen layer (e.g., thickness and material) are selected such that the structural integrity of the inner collagen layer is maintained during the first seven days after implantation of the stent in a human or animal body, but will be completely degraded within 28 days after implantation of the stent in a human or animal body.

[0026] Those skilled in the art will recognize that there are many materials and thicknesses that can achieve the desired degradation profile, and they will select the properties of the inner and outer collagen layers accordingly.

[0027] Preferably, the vascular stent has a length of 55 mm to 65 mm (eg, about 60 mm). As needed, the vascular stent can be cut into shorter lengths during surgery.

[0028] Alternatively, the vascular stent may be formed of an elongated portion; and a tubular portion that protrudes from the side of the elongated portion so that in use, the tubular portion can be positioned around the graft vessel of the end-to-side anastomosis, and the elongated portion can be positioned around the native vessel of the end-to-side anastomosis. Such a vascular stent may have a Y-shape or a T-shape. A more disc-like version may be constructed to cover the side-to-side anastomosis.

[0029] The tubular portion is preferably formed from the same inner and outer collagen layers as the elongate portion.

[0030] According to a second aspect of the present invention, there is provided a method of using the vascular stent of the first aspect in an arteriovenous bypass graft surgery. The surgery may optionally involve the use of synthetic graft material.

[0031] According to a third aspect of the present invention, there is provided a kit comprising: the vascular stent of the first aspect; and instructions for using the vascular stent in an arteriovenous bypass graft surgery. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Examples of the present invention will now be described in detail with reference to the accompanying drawings, in which:

[0033] Figure 1a An external stent is shown positioned at the site of the end-to-side anastomosis;

[0034] Figure 1bAn external stent is shown positioned at the site of an end-to-end anastomosis;

[0035] Figure 2a show Figure 1a A cross-sectional view of an external stent;

[0036] Figure 2b show Figure 1b A cross-sectional view of an external stent;

[0037] Figure 3a show Figure 1a or Figure 1b The outer layer of the external support (not Proportional );

[0038] Figure 3b show Figure 1a or Figure 1b Cross-sectional view of an external stent including a perforated outer layer.

[0039] Figure 4a Photo showing the collagen layer (dermis) without perforation;

[0040] Figure 4b show Figure 4b an enlarged view of a photograph;

[0041] Figure 4c Photograph showing the outer layer (dermis) of the external stent with perforations;

[0042] Figure 4d show Figure 4c an enlarged view of a photograph of; and

[0043] Figure 5a to Figure 5e A to-scale photograph showing an example perforation in the outer collagen layer (dermis). DETAILED DESCRIPTION

[0044] The present invention provides an improved external vascular stent for supporting vascular connections (anastomosis). When blood flow is restricted (for example due to smooth muscle cell neointimal hyperplasia (SMCNIH) or atherosclerosis), bypass surgery uses a portion of the patient's own healthy vessel (usually a vein) or a synthetic graft to reconnect the blood supply. As the reconnected blood vessel heals, the "scar" tissue on the inside of the vessel has a tendency to overgrow (SMCNIH), causing it to contract at the connection, resulting in reduced blood flow, turbulence, and a high risk of blood clot formation (thrombosis). The external stent of the device of the present invention inhibits the overgrowth of vascular SMCNIH tissue and promotes optimal healing of the connected vessels.

[0045] Figure 1aA Y-shaped stent 100 according to the present invention is shown. The stent 100 is placed around a blood vessel 200 formed by connecting a graft vessel 202 to a native vessel 201 at a stoma site in an end-to-side configuration. The stent 100 has an elongated portion 101 positioned around the native vessel 101 and a tubular portion 102 protruding from the side of the elongated portion 101 and positioned around the graft vessel 202. Although the stent 100 shown has the tubular portion 102 protruding at an acute angle relative to the elongated portion 101, it may also protrude at a different angle, such as a right angle (thus making the stent T-shaped).

[0046] The stent 100 shown also features a slit 103 in the elongated portion 101, which gives the elongated portion an arcuate cross-section when viewed in a plane perpendicular to the longitudinal axis of the elongated portion 101. Although the stent 100 shown surrounds most of the outer surface of the native vessel 201, the size of the slit 103 (and the resulting angle subtended by the arcuate cross-section) can vary. For example, the slit can be much larger so that the elongated portion 101 only surrounds the upper half of the native vessel 201, i.e., so that the elongated portion 101 "rides" on the native vessel 101. The arcuate configuration of the elongated portion 101 allows the stent 100 to be placed around the native vessel 201 without cutting through the native vessel 101.

[0047] The cross-section of tubular portion 102 is preferably elliptical (eg, circular), and graft vessel 202 is preferably passed through tubular portion 102 during surgery, although tubular portion 102 may alternatively have an arcuate cross-section similar to elongated portion 101 .

[0048] Figure 1b An alternative tubular stent 100 according to the present invention is shown. Figure 1b In the embodiment, the stent is positioned around a blood vessel 200 formed by connecting a graft vessel 202 to a native vessel 201 in an end-to-end configuration at an anastomosis site. In this example, the stent 100 includes only the elongated portion 101 and does not include a tubular portion. Since the stent 100 can be passed through either the native vessel 201 or the graft vessel 202 during surgery, there is no need for Figure 1b However, arrangements with slits (either pre-cut when the device is manufactured, or cut at the time of use during surgery) are also contemplated.

[0049] exist Figure 1a and Figure 1b Of the two, the extension portion 101 preferably has a length of 55mm to 65mm (eg 60mm). Generally speaking, once implanted, there will ideally be at least 2cm of overlap in any direction away from the line of the anastomosis, including on any synthetic graft used in the surgery.

[0050] Figure 2a and Figure 2b Display separately Figure 1a and Figure 1b A cross-sectional view of the stent 100 is shown in FIG. Figure 2a is a cross section taken along section line AA, and Figure 2b It is a cross section taken along section line BB.

[0051] like Figure 2a and Figure 2b As both shown, the elongate portion 101 has a laminated structure and is formed by an inner collagen layer 104 bonded to a surrounding outer collagen layer 105. Although not shown, the tubular portion 102 (if present) will typically have the same laminated structure as the elongate portion 101.

[0052] The outer collagen layer 105 is relatively rigid and acts as a scaffold to support the stoma after surgery, and also acts as a substrate onto which the inner collagen layer 104 can be applied.

[0053] The outer collagen layer 105 is preferably formed from a dermal collagen membrane derived from bovine (certified BSE-free) or porcine sources, which will preferably have undergone a viral inactivation process. The thickness of the outer collagen layer is preferably 0.1 mm to 1.0 mm.

[0054] In WO 2007 / 010295 A1, the outer layer is substantially non-porous. In contrast, the scaffold 100 of the present invention is characterized by a perforated outer collagen layer 105. Figure 3b As shown, only the outer collagen layer 105 is perforated, while the inner collagen layer 104 is not perforated. The use of the perforated outer collagen layer 105 allows microvessels to grow inward from the outside of the device and increases the size of the surface area of ​​the inner collagen layer that is presented to the microvessels from the beginning and can therefore be immediately engulfed. Accordingly, the inner collagen layer 104 is not perforated to maximize the amount of sponge material that can be used for biodegradation. The combination of the perforated outer layer 105 and the unperforated inner layer 104 ensures that the inner layer 104 biodegrades at a faster rate than the outer layer 105, thereby causing the success rate of arterial bypass grafts to increase.

[0055] like Figure 3a (not to scale), the perforated outer collagen layer 105 has a plurality of holes 106, preferably with a diameter of 0.1 mm to 5.0 mm. The spacing between adjacent / nearest neighboring holes (marked as d in FIG. 3) is preferably 1 mm to 10 mm. The holes 106 can be formed using any suitable process.

[0056] like Figure 3bAs shown, in an embodiment, the holes 106 may extend all the way through the perforated outer layer 105, but not into the non-perforated inner layer 104. As shown, the holes 106 may be symmetrically and equidistantly arranged around the perforated outer layer, but other arrangements are also contemplated.

[0057] Figure 4a and Figure 4b An exemplary collagen substrate (dermis) without pores is shown, and Figure 4c and Figure 4d An exemplary collagen substrate (dermis) is shown with pores 106. Further examples of collagen layers with pores suitable for use as the outer collagen layer 105 in the present invention are shown in Figure 5a to Figure 5e middle.

[0058] The outer collagen layer 105 has a degradation profile such that the structure should be retained for a minimum of three months after implantation.

[0059] The inner collagen layer 104 is biodegradable (i.e., degrades at a faster rate after implantation than the outer collagen layer 105) and is disposed within the outer collagen layer 105 such that the inner surface of the outer collagen layer contacts the outer surface of the inner collagen layer. The inner collagen layer 104 has a degradation profile such that ideally the structure should remain mostly intact for seven days and at most 28 days after implantation.

[0060] In addition, the inner collagen layer 104 has a composition that allows good adhesion to the outer collagen layer 105 during processing, and the outer collagen layer 105 has a structure that allows good adhesion of the inner collagen layer 104 during processing.

[0061] According to an exemplary embodiment, the collagen material for the inner collagen layer can be prepared as a suspension in sterile water. It can then be optionally filtered before being injected into the center of the mold defined by the outer collagen layer 105. Ideally, the resulting scaffold 100 will have a confluent coating (inner collagen layer 104) of collagen material throughout the outer collagen layer 105 of the elongated portion 101 and the tubular portion 102, with a consistent / uniform thickness and no gaps in the coating.

[0062] As with the outer collagen layer 105, the inner collagen layer 104 is preferably formed from a collagen material from a bovine (certified BSE-free) or porcine source, which will preferably have undergone a viral inactivation process.

[0063] The stent 100 of the present invention is a single-use device and is preferably distributed in a sealed sterile package as part of a kit including the stent 100 and instructions for use (IFU).

Claims

1. A vascular stent for placement around the outside of a circulatory anastomosis, the vascular stent comprising a laminate having a non-perforated biodegradable inner collagen layer and a perforated outer collagen layer arranged around the non-perforated biodegradable inner collagen layer. The vascular stent according to claim 1 , wherein the perforated outer collagen layer comprises a plurality of pores. 3 . The vascular stent according to claim 2 , wherein each of the plurality of holes has a diameter of 0.1 mm to 5.0 mm, preferably 0.1 mm to 0.5 mm. The vascular stent according to claim 2 or claim 3, wherein the distance between adjacent holes is 1 mm to 10 mm.

5. The vascular stent according to any preceding claim, wherein the profile of the vascular stent is elliptical or arcuate in a plane perpendicular to the longitudinal axis of the vascular stent.

6. The vascular stent according to any preceding claim, wherein the perforated outer collagen layer has a thickness of 0.1 mm to 1.0 mm.

7. The vascular stent according to any preceding claim, wherein the perforated outer collagen layer has a degradation profile such that the perforated outer collagen layer is retained for at least three months after implantation in a human or animal body.

8. The vascular stent according to any preceding claim, wherein the biodegradable inner collagen layer has a degradation profile such that the biodegradable inner collagen layer is retained for a minimum of seven days after implantation in a human or animal body.

9. The vascular stent according to any preceding claim, wherein the biodegradable inner collagen layer has a degradation profile such that the biodegradable inner collagen layer remains for a maximum of 28 days after implantation in a human or animal body.

10. The vascular stent according to any preceding claim, wherein the vascular stent has a length of 55 mm to 65 mm.

11. The vascular stent according to any preceding claim, wherein the vascular stent is formed by: elongated portion; and a tubular portion which protrudes from a side of the elongated portion, Such that, in use, the tubular portion is positionable around a graft vessel of an end-to-side anastomosis and the elongate portion is positionable around a native vessel of the end-to-side anastomosis.

12. Use of a vascular stent according to any preceding claim in arteriovenous bypass graft surgery.

13. A kit comprising: The vascular stent according to any one of claims 1 to 11; as well as Instructions for using the vascular stent in arteriovenous bypass graft surgery.

Citation Information

Patent Citations

  • stent

    WO2007010295A1

Cited By

  • Extravascular stent

    CN120168762A